Printer Friendly

Corporate Profile for Zonagen, dated May 21, 1999.

--(BUSINESS WIRE)--

The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-

Published Date: May 21, 1999

Company Name: Zonagen, Inc.

Address: 2408 Timberloch Place, B-4
 The Woodlands, Texas 77380

Main Telephone
 Number: 281/367-5892

Internet Home
 Page Address
 (URL) http://www.zonagen.com

Chief Executive
 Officer: Joseph S. Podolski

Chief Financial
 Officer: F. Scott Reding

Investor Relations
 Contact: Jean Anne Mire
 Business number: 281/719-3490
 e-mail address: jamire@zonagen.com

Trading Symbol/
 Exchange: Nasdaq:ZONA PCX:ZNG

Industry: Biotechnology

Market Makers: VOLP, CIBC


Company description: Zonagen Inc. is developing pharmaceutical products that address a broad spectrum of adult reproductive health problems, including drugs for the treatment of sexual dysfunction, urological disorders, contraception and infertility. The Company's products that are most advanced in clinical development focus on the treatment of male and female sexual dysfunction. ZONA employs a business strategy designed to provide a continuing pipeline of new products derived from its own research programs, as well as through an active acquisition strategy.

Vasomax(R) is the Company's first product, an oral treatment for Male Erectile Dysfunction (MED) that is a proprietary form of phentolamine mesylate delivered in a rapidly disintegrating tablet. In July 1998 the Company submitted an NDA for Vasomax(R) to the FDA, and in September, announced that its worldwide marketing partner, Schering-Plough Corporation, had submitted a Marketing Authorization Application to the Medicines Control Agency in the U.K. Both applications are under review.

ZONA also began a Phase I study of Vasofem in December 1998 for the treatment of Female Sexual Dysfunction (FSD). Vasofem is a vaginal dosage form of phentolamine mesylate, the active ingredient in Vasomax(R).

In addition to Vasomax(R) and Vasofem, ZONA is conducting pilot studies in Mexico for MED, including Bimexes, a second-generation combination oral therapy, and ERxin, a multi-component penile injection therapy. ZONA also has active research programs in urology, contraception and infertility. In November 1998 the Company began a pilot study in Mexico with Zproxal, a therapeutic vaccine for the treatment of prostate cancer.
COPYRIGHT 1999 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1999, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:May 21, 1999
Words:365
Previous Article:Corporate Profile for SportsTicker Enterprises, L.P., dated May 21, 1999.
Next Article:Corporate Profile for Vivid Technologies, Inc., dated May 21, 1999.
Topics:


Related Articles
Zonagen commences Phase III trials for Vasomax.
Michael T. Redman Joins Zonagen as Vice President of Business Development.
Zonagen Reports Fourth Quarter and 1998 Year-End Results.
Zonagen Announces Schering-Plough to Manufacture Vasomax.
Zonagen Announces Sale of Fertility Technologies Subsidiary to SAGE BioPharma.
Zonagen Reports First Quarter Results.
Zonagen Focuses Resources On Vasomax and Vasofem; Reduces Cash Expenditures.
Zonagen Reports Third Quarter Financial Results.
Corporate Profile for Zonagen, dated Jan. 25, 2002.
OMRON Healthcare Announces Dissolution of Affiliated Company.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters